Ledipasvir

Independent reference data for Ledipasvir (CAS 1256388-51-8), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Physicochemical values on record

Documented uses on record

When used in combination with the antiviral medication [sofosbuvir], ledipasvir is indicated for the treatment of treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age and older with the following conditions: - Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis. - Genotype 1 infection with decompensated cirrhosis, in combination with [ribavirin]. - Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensatedBreast Feeding; Lactation; Milk, Human; Antiviral Agents; NS5A Inhibitors

Synonyms and trade names

Ledipasvir; 1256388-51-8; GS-5885; GS5885; GS 5885; WHO 9796; 013TE6E4WV; CHEBI:85089; DTXSID90154829; HARVONI COMPONENT LEDIPASVIR; ledipasvirum; RefChem:798885; DTXCID8077320; Ledipasvir acetonate; Ledipasvir [USAN:INN]; MFCD25976756

Regulatory listings held on file

GHS notification summary	50% (1 / 2)

GHS hazard classification

GHS notification summary	50% (1 / 2)
Reported hazard statements	H371 (50%)

This chemical does not meet GHS hazard criteria for 50% (1 of 2) of reports.

H371 (50%): May cause damage to organs [Warning Specific target organ toxicity, single exposure]

What the public record says

Ledipasvir · CAS 1256388-51-8 · C49H54F2N8O6. UNII 013TE6E4WV. LogP: 3.8; Dissociation Constants: pka1 = 4.0, pka2 = 5.0.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.